Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov ID: NCT00080223

Public ClinicalTrials.gov record NCT00080223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).

Study identification

NCT ID: NCT00080223
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 83 participants

Conditions and interventions

Conditions

Interventions

Pirfenidone Drug

Drug

Eligibility (public fields only)

Age range: 40 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2003 (Actual)
Primary completion: Apr 30, 2015 (Actual)
Completion: Apr 30, 2015 (Actual)
Last update posted: Apr 17, 2017

2003 – 2015

United States locations

U.S. sites: 27
U.S. states: 18
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85006	—
Not listed	Pomona	California	91767	—
Not listed	San Jose	California	95119	—
Not listed	New Haven	Connecticut	06520	—
Not listed	Sarasota	Florida	34239	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Kailua	Hawaii	96734	—
Not listed	Lahaina	Hawaii	96761	—
Not listed	Nampa	Idaho	83686	—
Not listed	Elk Grove Village	Illinois	60007	—
Not listed	Boston	Massachusetts	02118	—
Not listed	West Roxbury	Massachusetts	02132	—
Not listed	St Louis	Missouri	63110	—
Not listed	Huntington Station	New York	11746	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10029-6574	—
Not listed	Rochester	New York	14620	—
Not listed	Worthington	Ohio	43085	—
Not listed	Portland	Oregon	97220	—
Not listed	Portland	Oregon	97227	—
Not listed	Lancaster	Pennsylvania	17601	—
Not listed	Dallas	Texas	75390-8503	—
Not listed	Houston	Texas	77005	—
Not listed	San Antonio	Texas	78229	—
Not listed	Provo	Utah	84604	—
Not listed	Annandale	Virginia	22003	—
Not listed	Bremerton	Washington	98310 - 3349	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00080223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 17, 2017 · Synced Oct 13, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00080223 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →